PPP2R1B Antibody

What is PPP2R1B and what is its biological significance?

PPP2R1B (Protein Phosphatase 2 Regulatory Subunit A Beta) functions as a constant regulatory subunit of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase that regulates numerous fundamental cellular processes . Recent research demonstrates that PPP2R1B plays a critical role in mediating meiotic progression during spermatogenesis, with homozygous deletion of Ppp2r1b in mouse models impairing meiotic recombination and causing meiotic arrest in spermatocytes . PPP2R1B has gained significant research interest as mutations in this scaffold subunit have been identified in various cancer types and in azoospermia patients with meiotic arrest .

What are the key specifications of commercially available PPP2R1B antibodies?

Most commercially available PPP2R1B antibodies are polyclonal antibodies produced in rabbits, though monoclonal variants exist as well . These antibodies typically target specific amino acid sequences, with some binding to N-terminal regions (AA 35-84), others to C-terminal regions (AA 402-601), and some to the full-length protein (AA 1-601) . The calculated molecular weight of the target protein is approximately 74 kDa (667 amino acids), though the observed molecular weight typically ranges between 60-74 kDa in experimental conditions . These antibodies generally show reactivity with human, mouse, and rat samples, though cross-reactivity varies between products .

How is PPP2R1B regulated at the post-translational level?

PPP2R1B undergoes significant post-translational regulation, particularly through ubiquitination pathways. Recent research has identified that PPP2R1B is susceptible to degradation by an E3 ligase complex CRL4A DCAF6 (Cullin-RING ligase 4A with DDB1-CUL4 associated factor 6) . Additionally, PPP2R1B stability is maintained through de-polyubiquitylation by ubiquitin-specific protease 5 (USP5), and certain mutations in PPP2R1B can render it resistant to this protective deubiquitination . This ubiquitination-based regulation plays a crucial role in controlling PPP2R1B protein levels, which in turn affects PP2A complex formation and function in cellular processes including meiosis .

What applications are PPP2R1B antibodies validated for?

PPP2R1B antibodies have been validated for multiple experimental applications, with comprehensive performance data available. The primary applications include Western Blot (WB) at dilutions ranging from 1:1000-1:4000, Immunohistochemistry (IHC) at dilutions of 1:50-1:500, and Immunofluorescence (IF)/Immunocytochemistry (ICC) at 1:50-1:500 dilutions . Additionally, these antibodies have demonstrated utility in Co-immunoprecipitation (CoIP) experiments and ELISA assays . Published research has successfully employed PPP2R1B antibodies in knockout/knockdown validation studies, further confirming their specificity and utility in functional genomics research .

What tissue and cell types have been validated for PPP2R1B antibody detection?

Validation data indicates successful detection of PPP2R1B in multiple sample types. For Western blotting, positive detection has been confirmed in A2780 cells, HeLa cells, human kidney tissue, and mouse and rat testis tissues . In immunohistochemistry applications, human liver tissue has shown positive results, particularly when using TE buffer pH 9.0 for antigen retrieval (though citrate buffer pH 6.0 can serve as an alternative) . For immunofluorescence applications, Caco-2 cells have been validated as a positive control . This cross-species reactivity makes these antibodies versatile tools for comparative studies between human and rodent models.

What is the recommended protocol for Western blot detection of PPP2R1B?

For optimal Western blot detection of PPP2R1B, researchers should begin with sample preparation in appropriate lysis buffer with protease inhibitors, considering that PPP2R1B is regulated by ubiquitination pathways . For gel electrophoresis, standard SDS-PAGE conditions suffice, with 10-12% acrylamide gels being suitable for resolving the 60-74 kDa protein . Following transfer to appropriate membranes, blocking with 5% non-fat milk or BSA in TBST is recommended. Primary antibody should be applied at dilutions between 1:1000-1:4000, with overnight incubation at 4°C yielding best results . After washing, standard HRP-conjugated secondary antibodies can be used, followed by ECL detection. Researchers should expect bands between 60-74 kDa, with possible variation depending on post-translational modifications and tissue source .

How can researchers optimize antigen retrieval for immunohistochemical detection of PPP2R1B?

Successful immunohistochemical detection of PPP2R1B depends critically on effective antigen retrieval. The primary recommended method is heat-induced epitope retrieval using TE buffer at pH 9.0, which has been validated for detection in human liver tissue . If suboptimal results are obtained, an alternative approach using citrate buffer at pH 6.0 can be attempted . For formalin-fixed paraffin-embedded tissues, retrieval time should be optimized between 10-20 minutes at 95-100°C, followed by cooling to room temperature. Signal enhancement may be achieved through the use of polymer-based detection systems rather than traditional ABC methods. Additionally, titration experiments are essential, as the optimal antibody concentration ranges from 1:50-1:500 depending on the specific tissue and fixation protocol employed .

What strategies can address weak or nonspecific signals in PPP2R1B immunodetection?

When confronting weak signals in PPP2R1B detection, several optimization strategies can be employed. For Western blotting, increasing protein loading (50-80 μg), extending primary antibody incubation to overnight at 4°C, and employing signal enhancement reagents can improve detection sensitivity . For immunohistochemistry and immunofluorescence, signal amplification systems and tyramide signal amplification can overcome low expression levels. To address nonspecific binding, stringent blocking with 5% BSA with 0.3% Triton X-100 is recommended, possibly supplemented with normal serum matching the secondary antibody species. Including proper negative controls (primary antibody omission, isotype controls, and ideally knockout/knockdown samples) is essential for distinguishing specific from nonspecific signals . Additionally, researchers should be aware that PPP2R1B protein levels may be regulated by ubiquitination, potentially resulting in variability across different tissue samples or experimental conditions .

How can researchers validate PPP2R1B antibody specificity in their experimental system?

Comprehensive validation of PPP2R1B antibody specificity requires a multi-faceted approach. The gold standard involves conducting parallel experiments using knockout or knockdown models, which have been successfully employed in published PPP2R1B studies . For human samples where genetic models are unavailable, peptide competition assays can be performed by pre-incubating the antibody with excess immunizing peptide, which should eliminate specific signals. Cross-validation using multiple antibodies targeting different epitopes of PPP2R1B can provide additional confidence. When analyzing Western blot results, researchers should confirm that the observed molecular weight matches the expected range (60-74 kDa) while being aware that post-translational modifications, particularly ubiquitination, can affect migration patterns . For immunolocalization, correlation with mRNA expression data from public databases can help confirm expression patterns across tissues and cell types.

How can PPP2R1B antibodies be employed in studying protein-protein interactions within the PP2A complex?

The PP2A holoenzyme functions as a heterotrimeric complex comprising a catalytic C subunit, a scaffolding A subunit (including PPP2R1B), and a variable regulatory B subunit. Co-immunoprecipitation (CoIP) using PPP2R1B antibodies has been validated as an effective approach for studying these interactions . For optimal results, researchers should employ mild lysis conditions (typically containing 0.5% NP-40 or Triton X-100) to preserve protein complexes while adding phosphatase inhibitors to maintain the physiological phosphorylation state. Cross-linking with DSP (dithiobis[succinimidylpropionate]) prior to lysis can stabilize transient interactions. Quantitative mass spectrometry following PPP2R1B immunoprecipitation allows for the identification of novel interaction partners and regulatory B subunits that associate with PPP2R1B-containing PP2A complexes under various cellular conditions. For visualization of these interactions in situ, proximity ligation assays (PLA) can be combined with PPP2R1B immunofluorescence to map the subcellular locations where PPP2R1B-containing PP2A complexes assemble .

What approaches can be used to study PPP2R1B's role in meiotic progression?

Recent research has established PPP2R1B's critical role in meiotic progression during spermatogenesis . To investigate this function, researchers can employ dual immunofluorescence staining with PPP2R1B antibodies (1:50-1:500 dilution) alongside markers of meiotic structures such as synaptonemal complex proteins SYCP1 and SYCP3, or the recombination marker MLH1 . This approach enables visualization of PPP2R1B localization during different stages of meiotic prophase I. For functional studies, conditional knockout models in germline cells provide the most definitive insights, as homozygous deletion of Ppp2r1b impairs meiotic recombination and causes meiotic arrest in spermatocytes . In human studies, immunohistochemical analysis of testicular biopsies from azoospermia patients can be performed to correlate PPP2R1B expression or localization patterns with meiotic arrest phenotypes . Additionally, targeted sequencing of PPP2R1B in patient cohorts can identify potentially pathogenic variants, which can then be functionally characterized using in vitro stability assays to assess their susceptibility to ubiquitination and degradation .

How can researchers investigate PPP2R1B's post-translational regulation by ubiquitination?

To study the ubiquitination-dependent regulation of PPP2R1B, researchers can employ several complementary approaches. Protein stability can be assessed through cycloheximide chase assays, where cells are treated with the protein synthesis inhibitor cycloheximide (CHX) and PPP2R1B levels are monitored over time by Western blotting . To directly detect ubiquitinated PPP2R1B, immunoprecipitation with PPP2R1B antibodies followed by immunoblotting with anti-ubiquitin antibodies is effective. For more specific analysis, cells can be transfected with His-tagged ubiquitin followed by nickel affinity purification under denaturing conditions to isolate all ubiquitinated proteins, then probed for PPP2R1B. The role of specific E3 ligases (such as CRL4A DCAF6) or deubiquitinating enzymes (like USP5) can be investigated through siRNA knockdown, CRISPR knockout, or pharmacological inhibition, followed by assessment of changes in PPP2R1B stability or ubiquitination levels . For clinical relevance, patient-derived mutations can be introduced into expression constructs and their effects on protein stability and ubiquitination susceptibility can be examined in cellular models.

What is the significance of PPP2R1B mutations in human diseases?

PPP2R1B mutations have significant implications in multiple disease contexts. In cancer biology, mutations in the PPP2R1B gene have been identified in several tumor types, establishing it as a potential tumor suppressor gene . More recently, heterozygous missense mutations in PPP2R1B have been discovered in azoospermia patients with meiotic arrest, directly linking PPP2R1B dysfunction to male infertility . Mechanistic studies have revealed that certain PPP2R1B mutants show increased susceptibility to degradation by the E3 ligase CRL4A DCAF6 while becoming resistant to deubiquitylation by USP5 . Furthermore, these heterozygous mutations demonstrate a dominant negative effect by reducing the stability of wild-type PPP2R1B protein, explaining how even heterozygous mutations can cause significant functional impairment . These findings highlight the therapeutic potential of targeting the ubiquitination pathway to stabilize PPP2R1B in patients with specific mutations.

How can PPP2R1B antibodies be used in diagnostic or prognostic applications?

While primarily research tools, PPP2R1B antibodies have potential utility in diagnostic and prognostic applications, particularly in reproductive medicine and oncology. In male infertility cases, immunohistochemical analysis of testicular biopsies using PPP2R1B antibodies (at 1:50-1:500 dilution) can help identify patients with defective PPP2R1B expression or localization . This approach could assist in classifying different types of meiotic arrest and guide genetic testing decisions. In cancer research, altered PPP2R1B expression patterns may correlate with tumor progression or treatment response, making PPP2R1B immunodetection a candidate prognostic marker for certain malignancies . For clinical applications, immunohistochemical protocols must be standardized and validated across different laboratories, ideally using automated staining platforms. The development of phospho-specific PPP2R1B antibodies could further enhance diagnostic precision by detecting specific post-translational modifications associated with disease states. As with any potential biomarker, rigorous validation in large patient cohorts is essential before clinical implementation.

What future research directions are emerging for PPP2R1B in therapeutic development?

The recent elucidation of PPP2R1B's role in spermatogenesis and its regulation by ubiquitination pathways opens several promising avenues for therapeutic development . For male infertility associated with PPP2R1B mutations, targeted inhibition of the E3 ligase CRL4A DCAF6 or enhancement of USP5 deubiquitinase activity could theoretically stabilize mutant PPP2R1B protein and rescue its function . Small molecule screens aimed at identifying compounds that stabilize PPP2R1B, either by directly binding the protein or by modulating its interaction with the ubiquitination machinery, represent a logical next step. In cancer contexts where PPP2R1B functions as a tumor suppressor, similar stabilization approaches could potentially restore its activity. Alternatively, synthetic lethality strategies could be explored to specifically target cells with PPP2R1B mutations. For all these applications, the availability of high-quality, well-characterized PPP2R1B antibodies will be essential for screening assays, target validation, and pharmacodynamic studies to monitor treatment effects on PPP2R1B levels and localization in preclinical models .